Article

Structured Early RA Intervention Programs More Effective

In early rheumatoid arthritis, structured treatment programs are better than usual treatment for improving activity and preventing progression.

For patients with early rheumatoid arthritis (RA), structured treatment programs in early arthritis clinics are more effective in improving activity and preventing major radiographic progression than nonprotocolized referral and follow-up. A clinic should be able to provide easy access to expert consultation within 2 weeks of referral.

Descalzo and associates compared an RA cohort from reference hospitals in which a specific intervention was established and a historical control cohort of patients with early RA attending rheumatology departments. They tested treatment effectiveness by comparing changes in the Disease Activity Score in 28 joints (DAS 28), the Health Assessment Questionnaire (HAQ), and the Sharp/van der Heijde radiologic score.

Intervention was inversely correlated with disease activity, resulting in a decrease of −0.24 units in the population average of the DAS 28 after adjustment. The total Sharp/van der Heijde score at baseline, rheumatoid factor positivity, and time were associated with radiographic progression, but intervention may be seen as a protective factor of radiologic damage, especially for erosions. Although a decrease in functional impairment was detected, intervention was not statistically associated with HAQ decrements after adjustment.

The authors suggested that the study of RA in its early stages should be a research priority and management of RA in its early stages should be a priority in health care delivery.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.